SOMAÍ Pharmaceuticals

Home
Australia
Brisbane, QLD
SOMAÍ Pharmaceuticals

Somai is fast becoming one of the most recognized and well-developed pharmaceutical brands in the EU.

A leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio Somai Pharmaceuticals LTD is a European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal and distribution of EU GMP-certified cannabinoid-containing pharmaceuticals throughout the European Union and globally. Somai emphasizes scientific pharmacology applications with EU-GMP standards to deliver treatments to the endocannabinoid system, effectively and with consistency across all markets. Somai's product development knowledge was honed in the competitive American market, and is the largest and most advanced cannabinoid manufacturing facility across legal European markets producing medicines products and registered API's. Somai has brought together an all-star team of scientists and KOL's from around the world with various clinical experiences to guide Somai's product development and acceptance globally. Somai stresses education and continual R&D, which started from the USA as transformative developments, to help EU doctors and patients properly diagnose and treat the individual indications by providing variable dosage choices. Somai’s primary goal is producing the most advanced products with the most innovative delivery methods to create maximum bioavailability and healing for patients. As a global biotech player concentrating on cannabinoids, Somai has a unique pipeline of current and future products that will be on the market starting in late 2022. They already boast one of the largest IP (Intellectual Property) vaults of APIs that weren’t accessible to Europe until recently. Somai’s near term products conform to the highest standards of herbal medicine (ACM) and specialized cannabinoid API’s for R&D, but also keeps a steady eye on the horizon of future clinical trials for their proprietary pipeline, setting it up to be well positioned for the next decade.

29/01/2026

We’re heading to Brisbane!

SOMAÍ is a Bronze Sponsor of UIC 2026 and we’ll be on the expo floor all conference long.

Be sure to catch CEO Michael Sassano’s talk on our latest scientific publications, and then swing by our booth to learn from Sam, Renee & Judi.

Catch you February 26-28.

20/01/2026

SOMAÍ today announced that it has received official approval from INFARMED, Portugal’s National Authority of Medicines and Health Products, to commercialize three of its medical cannabis products in Portugal, and also received independently a Portuguese GDP distribution license that enables direct commercialization and supply.

This market authorization ACM and distribution license approval marks a significant milestone for SOMAÍ, enabling the company to supply the Portuguese medical cannabis market with EU-GMP-certified cannabinoid medicines manufactured in Portugal, in full compliance with national and European regulatory standards.

“This approval represents an important moment for SOMAÍ and for Portugal’s medical cannabis ecosystem,” said Sassano, Founder and Interim CEO of SOMAÍ. “Having an official medical market-authorized product in Portugal and the EU is another milestone accomplished that will supply Portuguese patients, but the bigger picture is that SOMAÍ has already invested significantly in developing comprehensive regulatory dossiers that can access the hardest medical markets in European and global markets, including Spain, France, Poland, New Zealand, and other strictly medical markets. SOMAÍ's investment in dossiers further reinforces our strategy to reach all cannabis markets and provide access to our extract portfolio to patients in all approved markets.”

Read the full news here: https://www.einpresswire.com/article/884621464/soma-secures-product-and-distribution-authorization-in-portugal

13/01/2026

SOMAÍ and Universidade Lusófona - Centro Universitário Lisboa have published their 4th peer-reviewed study titled “Genotype and chemotype insights of high-THC medicinal Cannabis sativa L.: the role of SSR markers in the identification of cultivars” in the Journal of Cannabis Research.

The paper presents a scientifically validated framework that supports genetic and chemical consistency in high-THC medicinal cannabis oils—reinforcing SOMAÍ’s commitment to evidence-based pharmaceutical manufacturing and regulatory excellence across global medical markets.

“At SOMAÍ, we are making more than an extensive product array; we continue to invest in scientific studies to differentiate our products for doctors and patients around the globe. With a belief that pharmaceutical cannabis demands the same rigor as any other medicinal product, this study demonstrates how genetics, chemistry, and GMP processes work together to guarantee consistency for patients and confidence for prescribers,” said Michael Sassano, Founder and Interim CEO of SOMAÍ. “As more markets adopt higher regulatory expectations, Somai will continue to be first in researching the future of cannabis-based extract medicines.”

“This research provides the scientific framework needed to guarantee batch-to-batch consistency in cannabis medicines. By integrating genotype and chemotype verification, we are able to confirm the reliability and reproducibility expected in any pharmaceutical product,” said Professor Maria do Céu Costa of Universidade Lusófona. “Working with SOMAÍ allowed us to translate this methodology directly into real-world EU-GMP manufacturing, ensuring patients benefit from truly standardized formulations.”

Read the news: https://www.einpresswire.com/article/882572511/soma-and-universidade-lus-fona-publish-peer-reviewed-study-validating-full-spectrum-oil-consistency

05/01/2026

SOMAÍ announces the launch of its Mint Oral Solutions line in Switzerland, marking the next phase of its collaboration with Dascoli Pharma AG.

The Mint Oral Solutions line has been developed to combine pharmaceutical precision with improved patient compliance and treatment adherence. Created using SOMAÍ’s advanced purification process, the formulations feature a refreshing peppermint terpene mix that offers a more pleasant experience for patients requiring long-term treatment. Each product in the line maintains consistent cannabinoid profiles, high bioavailability, and EU-GMP-certified quality, reflecting SOMAÍ’s commitment to innovation and patient-centric design.

“Our ongoing collaboration with Dascoli Pharma AG allows SOMAÍ to continue expanding access to our cannabinoid formulations through a trusted partner that shares our vision of pharmaceutical integrity and medical compliance,” said Michael Sassano, Founder of SOMAÍ. “The introduction of the Mint Oral Solutions line builds on the success of our Essentuals range and reinforces SOMAÍ’s position as a leader in EU-GMP cannabinoid-based medicines.”

Read the full news here: https://somaipharma.eu/news/somai-expands-partnership-with-dascoli-pharma-ag-to-launch-mint-oral-solutions-line-in-switzerland/

30/12/2025

🔹 Ending 2025 with a conversation about what comes next.

On the latest Give and T**e episode, host Paul O’Donoghue is joined by SOMAÍ’s Interim CEO and Founder, Michael Sassano — a leader known for calling global market shifts early — to look back at 2025 and explore what 2026 could bring across the world.

🌀 Market outlooks
🌍 Global trends
🔵 What to watch in 2026

🎧 Tune in: https://giveandtoke.transistor.fm/episodes/what-2025-taught-us-about-global-cannabis-w-michael-sassano-somai

🔹 And stay tuned for what will bring in 2026.

22/12/2025

The second half of this year has flown by. Our SOMAÍ Australia team has been on the move - attending conferences, building new relationships, reconnecting with familiar faces, and visiting clients across the country. We travelled to Thailand for an education tour of cultivation facilities, deepened our industry connections, supported dispensaries and clinics, engaged with prescribers, and listened to the experiences of patients.

It’s been rewarding, and we can't wait for 2026.

18/12/2025

🔹 Trump officially signs an order to reclassify cannabis to Schedule III (December 18, 2025) — a step that recognizes medical value and should make research and patient access easier, while still stopping short of full federal legalization.
Reuters

SOMAÍ Founder Michael Sassano shared:
“Trump took the common sense approach and did what others promised, rescheduled cannabis as an accepted medicine. Long awaited, this sends a message around the globe that medical cannabis should be available to help people and not providing access is simply bad political policy.”

What matters most: patients. If cannabis is treated as medicine, the systems around it should support responsible access, evidence-based regulation, and continued clinical research.

This development aligns with what Michael forecast earlier this year in his Honeysuckle Magazine article: https://honeysucklemag.com/trump-make-cannabis-great-again-schedule-iii-legalization/

16/12/2025

Together, we’re bringing some of the world’s most sought-after genetics into a pharmaceutical-grade framework - ensuring patients can access trusted, high-quality medicinal products.

Quality. Consistency. Innovation.

Cookies

15/12/2025

Establishing a consistent cannabis product brand is a complicated task. The cannabis industry will always be home to mainstream local brands, craft local brands, large global brands, and craft global brands all co-existing in the same space. The good news is there is room for everyone. The bad news is that supply line issues and the resulting lack of consistency plague the global cannabis industry, affecting players of every size.

When it comes to cannabis branding, it’s not enough to just carry the name from country to country. Owning the quality is the key to success.

Read the latest article by Michael Sassano published in Krautinvest: https://krautinvest.de/the-problem-of-consistency-in-local-and-global-cannabis-branding/

02/12/2025

A key difference between a medically certified oil vaporizer and a non-medically approved one lies in their regulatory standard. Non-medical units are often consumer-grade devices designed without stringent oversight of materials, manufacturing, or long-term product stability. In contrast, medically certified vaporizers must meet the same rigorous requirements as other pharmaceutical equipment. This includes using medical-grade materials, meeting biological testing standards such as 10993 and 18562, and demonstrating that the device delivers a consistent dose of medicine over its entire lifespan. This provides a crucial level of assurance for doctors, pharmacists, and insurance companies that is absent with uncertified consumer devices.

Read the full article by Michael Sassano here: https://cannareporter.eu/en/2025/12/02/EU-certified-medical-vaporizers-are-entering-the-market--setting-a-new-regulatory-standard./

airobrands official

24/11/2025

We’re proud to announce the launch of Soma OG in the United Kingdom — SOMAÍ’s in-house flower brand.

Soma OG is synonymous with premium quality, featuring indoor-cultivated, non-irradiated, hand-trimmed flowers. Every step of the process is carefully controlled to ensure authenticity and excellence — from seed to the sophisticated packaging that reflects the essence of a truly “OG” product.

Each batch is grown in small, controlled environments, hand-selected by SOMAÍ’s global cultivation network, and verified under EU-GMP and GACP standards.

The launch of Soma OG expands SOMAÍ’s portfolio in the UK, strengthening our commitment to serving patients through regulated medical channels. Soma OG will be available across the country, ensuring broad and reliable patient access.

At SOMAÍ, we believe that consistency, value, and patient trust define true medical excellence. Soma OG embodies this philosophy — delivering carefully crafted flower designed to meet the highest pharmaceutical expectations while honoring the natural essence of the plant.

Learn more: www.somaipharma.eu
Contact: hello@somaipharma.eu

17/11/2025

Members of our Australian team recently visited Thailand, gaining firsthand insight into the exceptional care, precision and controlled indoor environments driving Thailand’s next generation of cannabis cultivation.

This visit served as a reminder that perceptions of Thai cannabis are evolving, and deservedly so. Behind the headlines and assumptions lies a growing pharmaceutical-grade ecosystem, one we are proud to integrate into our global supply network.

Address

Brisbane, QLD

Website

http://www.somaipharma.eu/

Alerts

Be the first to know and let us send you an email when SOMAÍ Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to SOMAÍ Pharmaceuticals:

Want your practice to be the top-listed Clinic in Brisbane?